Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-07-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/9/7/1727 |
| _version_ | 1827712814392803328 |
|---|---|
| author | Magalie Dosset Elodie Lauret-Marie Joseph Thaiz Rivera Vargas Lionel Apetoh |
| author_facet | Magalie Dosset Elodie Lauret-Marie Joseph Thaiz Rivera Vargas Lionel Apetoh |
| author_sort | Magalie Dosset |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also long-lasting tumor protection? How must the combined treatments be administered to the patients to harness their full potential while limiting adverse immunological events? Here, we address these points by reviewing how immunogenic anticancer therapies can provide novel therapeutic opportunities upon combination with ICPi. We discuss their ability to create a permissive tumor microenvironment through the generation of inflamed tumors and stimulation of memory T cells such as resident (T<sub>RM</sub>) and stem-cell like (T<sub>SCM</sub>) cells. We eventually underscore the importance of sequence, dose, and duration of the combined anticancer therapies to design optimal and successful cancer immunotherapy strategies. |
| first_indexed | 2024-03-10T18:22:39Z |
| format | Article |
| id | doaj.art-4f4edb4dff73479e8e6760ff2c17fc1d |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T18:22:39Z |
| publishDate | 2020-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-4f4edb4dff73479e8e6760ff2c17fc1d2023-11-20T07:15:19ZengMDPI AGCells2073-44092020-07-0197172710.3390/cells9071727Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint InhibitorsMagalie Dosset0Elodie Lauret-Marie Joseph1Thaiz Rivera Vargas2Lionel Apetoh3The Laboratory of Immunology, Department of Medicine and Moores Cancer Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0815, USALudwig Institute for Cancer Research, University of Lausanne, Agora Center, Rue du Bugnon 25A, 1005 Lausanne, SwitzerlandINSERM, U1231, 21000 Dijon, FranceINSERM, U1231, 21000 Dijon, FranceImmune checkpoint inhibitors (ICPi) have shown their superiority over conventional therapies to treat some cancers. ICPi are effective against immunogenic tumors. However, patients with tumors poorly infiltrated with immune cells do not respond to ICPi. Combining ICPi with other anticancer therapies such as chemotherapy, radiation, or vaccines, which can stimulate the immune system and recruit antitumor T cells into the tumor bed, may be a relevant strategy to increase the proportion of responding patients. Such an approach still raises the following questions: What are the immunological features modulated by immunogenic therapies that can be critical to ensure not only immediate but also long-lasting tumor protection? How must the combined treatments be administered to the patients to harness their full potential while limiting adverse immunological events? Here, we address these points by reviewing how immunogenic anticancer therapies can provide novel therapeutic opportunities upon combination with ICPi. We discuss their ability to create a permissive tumor microenvironment through the generation of inflamed tumors and stimulation of memory T cells such as resident (T<sub>RM</sub>) and stem-cell like (T<sub>SCM</sub>) cells. We eventually underscore the importance of sequence, dose, and duration of the combined anticancer therapies to design optimal and successful cancer immunotherapy strategies.https://www.mdpi.com/2073-4409/9/7/1727immunogenic therapyimmune checkpoint inhibitorscombined therapiescancerT cellsstem-cell like memory T cells |
| spellingShingle | Magalie Dosset Elodie Lauret-Marie Joseph Thaiz Rivera Vargas Lionel Apetoh Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors Cells immunogenic therapy immune checkpoint inhibitors combined therapies cancer T cells stem-cell like memory T cells |
| title | Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors |
| title_full | Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors |
| title_fullStr | Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors |
| title_full_unstemmed | Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors |
| title_short | Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors |
| title_sort | modulation of determinant factors to improve therapeutic combinations with immune checkpoint inhibitors |
| topic | immunogenic therapy immune checkpoint inhibitors combined therapies cancer T cells stem-cell like memory T cells |
| url | https://www.mdpi.com/2073-4409/9/7/1727 |
| work_keys_str_mv | AT magaliedosset modulationofdeterminantfactorstoimprovetherapeuticcombinationswithimmunecheckpointinhibitors AT elodielauretmariejoseph modulationofdeterminantfactorstoimprovetherapeuticcombinationswithimmunecheckpointinhibitors AT thaizriveravargas modulationofdeterminantfactorstoimprovetherapeuticcombinationswithimmunecheckpointinhibitors AT lionelapetoh modulationofdeterminantfactorstoimprovetherapeuticcombinationswithimmunecheckpointinhibitors |